AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32912741 — intervention group
Group type: COMPARATOR
Intervention: Uncoated GP lenses (9.6 mm diameter)
Number of subjects: 233
Study 32912741 — intervention group
Group type: EXPERIMENTAL
Intervention: All cohorts (plasma coated and uncoated)
Number of subjects: 233
Study 32725954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup 10 mg/kg
Number of subjects: 61
Study 32725954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 32725954 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive BAL culture
Number of subjects: 61
Study 32725954 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative BAL culture
Number of subjects: 61
Study 35596935 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (up to 40mg three times/day)
Number of subjects: 69
Study 35596935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 35596935 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 69
Study 33676458 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Food Delivery Services (OFDS)
Number of subjects: 480
Study 32588134 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE)
Number of subjects: 97
Study 32588134 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 97
Study 34837395 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative self-talk (NST)
Number of subjects: 29
Study 34837395 — intervention group
Group type: COMPARATOR
Intervention: Positive self-talk
Number of subjects: 29
Study 34837395 — intervention group
Group type: COMPARATOR
Intervention: Dissociative group (DG)
Number of subjects: 29
Study 33484082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension offloading device applied preoperatively
Number of subjects: 12
Study 33484082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension offloading device applied preoperatively and postoperatively
Number of subjects: 12
Study 33484082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study 34108184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 407
Study 34108184 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 407
Study 34108184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 407
Study 33275668 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel targeted agents (ibrutinib, acalabrutinib, venetoclax)
Number of subjects: 0
Study 33275668 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 33275668 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-free frontline treatment approaches
Number of subjects: 0
Study 36108617 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiparasitic antibiotic treatment in Group A
Number of subjects: 70
Study 36108617 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 70
Study 34231475 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality application during colonoscopy
Number of subjects: 60
Study 34231475 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy protocol
Number of subjects: 60
Study 33380030 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupling delays with two different values in a ring network of six oscillators.
Number of subjects: 6
Study 33380030 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental ring of six bidirectionally coupled Colpitts oscillators with delayed connections via RF cables.
Number of subjects: 6
Study 33380030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully connected network of fifty nodes with connections randomly assigned to be either undelayed or delayed.
Number of subjects: 6
Study 35902351 — intervention group
Group type: EXPERIMENTAL
Intervention: Olezarsen (50 mg every 4 weeks)
Number of subjects: 114
Study 35902351 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 114
Study 33296258 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure treatment (performed two times a week for 4 weeks)
Number of subjects: 50
Study 33296258 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 50
Study 32819444 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope (VL)
Number of subjects: 35
Study 32819444 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentax Airway Scope (AWS)
Number of subjects: 35
Study 32819444 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 35
Study 35115351 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control and manual therapy
Number of subjects: 40
Study 35115351 — intervention group
Group type: COMPARATOR
Intervention: General strength and conditioning (GSC)
Number of subjects: 40
Study 34615684 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath MAC videolaryngoscope
Number of subjects: 1000
Study 34615684 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy using the Macintosh laryngoscope
Number of subjects: 1000
Study 32629682 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 90
Study 35055807 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planning (SRP) plus gaseous ozone therapy (GROUP A)
Number of subjects: 90
Study 35055807 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (GROUP B)
Number of subjects: 90
Study 34551783 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal care during lockdown (20 April 2020 to 15 May 2020)
Number of subjects: 105
Study 34551783 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal care during lockdown
Number of subjects: 105
Study 34551783 — intervention group
Group type: EXPERIMENTAL
Intervention: Visiting caregivers during lockdown
Number of subjects: 105
Study 34551783 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-residing caregivers during lockdown
Number of subjects: 105
Study 34551783 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nursing care for PwD living alone during lockdown
Number of subjects: 105
Study 34551783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function impact on home nursing service during lockdown
Number of subjects: 105
Study 32209621 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided online mindfulness-focused intervention (StudiCare Mindfulness)
Number of subjects: 120
Study 32209621 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 120
Study 35706482 — intervention group
Group type: EXPERIMENTAL
Intervention: NEVERMIND e-health system (smart shirt and mobile application with lifestyle behavioural advice, mindfulness-based therapy, and cognitive behavioural therapy)
Number of subjects: 425
Study 35706482 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 425
Study 35489648 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (1mg/kg body weight Enoxaparin, subcutaneously, 12 hourly for seven days)
Number of subjects: 140
Study 35489648 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for pancreatitis (Control group)
Number of subjects: 140
Study 33684508 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral, lifestyle, and psychological therapy interventions
Number of subjects: 151
Study 35344461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis group intervention
Number of subjects: 95
Study 35344461 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 95
Study 32507850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use (lifetime, yes/no; 42 instrument SNPs; GWAS sample size = 162,082)
Number of subjects: 50
Study 32507850 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use (drinks-per-week; 53 instrument SNPs; N = 941,280)
Number of subjects: 50
Study 32507850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smoking initiation (yes/no; 156 instrument SNPs; N = 1,232,091)
Number of subjects: 50
Study 32507850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smoking heaviness (27 instrument SNPs; N = 337,334)
Number of subjects: 50
Study 32103747 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) point-of-care testing (POCT)
Number of subjects: 11
Study 32103747 — intervention group
Group type: COMPARATOR
Intervention: Care as usual without CRP POCT
Number of subjects: 11
Study 36130048 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rhGH 0.1 mg/kg/week (low-dose group)
Number of subjects: 360
Study 36130048 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rhGH 0.2 mg/kg/week (high-dose group)
Number of subjects: 360
Study 36130048 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study 36130048 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 360
Study 33855369 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 33855369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate/immature desmoplastic reaction
Number of subjects: 0
Study 33561857 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat
Number of subjects: 299
Study 33561857 — intervention group
Group type: COMPARATOR
Intervention: CERA (Epoetin Beta Pegol)
Number of subjects: 299
Study 33561857 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat and CERA
Number of subjects: 299
Study 32234534 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 331
Study 32234534 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 331
Study 35138997 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention
Number of subjects: 200
Study 35138997 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study 33111541 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Healthy, Work Healthy (LHWH)
Number of subjects: 359
Study 34261994 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (EX) for 12 weeks, goal of 200 min·wk−1
Number of subjects: 49
Study 34261994 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (EX)
Number of subjects: 49
Study 34261994 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control condition (CON)
Number of subjects: 49
Study 34775146 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-haploidentical relative bone marrow (Haplo-BM)
Number of subjects: 337
Study 34775146 — intervention group
Group type: COMPARATOR
Intervention: 2 umbilical cord blood (UCB) units
Number of subjects: 337
Study 34775146 — intervention group
Group type: COMPARATOR
Intervention: Nontrial Haplo-BM
Number of subjects: 337
Study 34775146 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplo-PB transplantation
Number of subjects: 337
Study 34496277 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy enhanced with Crisis Response Planning for suicide risk
Number of subjects: 0
Study 34496277 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Number of subjects: 0
Study 34496277 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 0
Study 35017325 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC; 1200 mg)
Number of subjects: 130
Study 35017325 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids (4 g)
Number of subjects: 130
Study 32335056 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivinex XY1 IOL
Number of subjects: 80
Study 32335056 — intervention group
Group type: COMPARATOR
Intervention: AcrySof SN60WF IOL
Number of subjects: 80
Study 34656813 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Dissonance (ED)
Number of subjects: 144
Study 34656813 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive Suppression (ES)
Number of subjects: 144
Study 34656813 — intervention group
Group type: COMPARATOR
Intervention: Control condition (naturally observe)
Number of subjects: 144
Study 32394024 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue milk
Number of subjects: 30
Study 32394024 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium, white water, and white milk
Number of subjects: 30
Study 32394024 — intervention group
Group type: COMPARATOR
Intervention: Blue water
Number of subjects: 30
Study 32902105 — intervention group
Group type: EXPERIMENTAL
Intervention: FDBA alone + collagen membrane (n = 21)
Number of subjects: 42
Study 32902105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FDBA and AB + collagen membrane (n = 21)
Number of subjects: 42
Study 32902105 — intervention group
Group type: COMPARATOR
Intervention: Comparison between FDBA and combined group
Number of subjects: 42
Study 34000049 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 180 mg/day
Number of subjects: 73
Study 34000049 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 60 mg/day
Number of subjects: 73
Study 34000049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 34000049 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Number of subjects: 73
Study 32860331 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib plus cisplatin-etoposide (CE)
Number of subjects: 128
Study 32860331 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cisplatin-etoposide (CE)
Number of subjects: 128
Study 32860331 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample adherence to oral therapy
Number of subjects: 128
Study 32860331 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent symptoms
Number of subjects: 128
Study 32860331 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically significant neurotoxicity
Number of subjects: 128
Study 32860331 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotoxicity scores
Number of subjects: 128
Study 33809826 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous, telephone-based internal health service models of nutrition care
Number of subjects: 13
Study 33809826 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application-based delivery methods
Number of subjects: 13
Study 33809826 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel technology for delivering nutrition care
Number of subjects: 13
Study 35088722 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative neurostimulator (ReActiv8)
Number of subjects: 204
Study 33388067 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet
Number of subjects: 74
Study 33388067 — intervention group
Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 74
Study 34743361 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 0
Study 34743361 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 0
Study 34743361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34743361 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib
Number of subjects: 0
Study 33008933 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on azithromycin (AZM)
Number of subjects: 420
Study 35684157 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGAT (combination of serine, alanine, glutamate, aspartate, and tyrosine)
Number of subjects: 42
Study 35684157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 33249630 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg HS-10234
Number of subjects: 36
Study 33249630 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg HS-10234
Number of subjects: 36
Study 33249630 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg HS-10234
Number of subjects: 36
Study 33249630 — intervention group
Group type: COMPARATOR
Intervention: 300 mg Tenofovir disoproxil fumarate (TDF)
Number of subjects: 36
Study 33249630 — intervention group
Group type: EXPERIMENTAL
Intervention: HS-10234
Number of subjects: 36
Study 36009012 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy/fat diet (1200–1500 Kcal/day and 15–20% lipids) + Monacolin K (5 mg) + Astaxanthin (0.1 mg)
Number of subjects: 80
Study 36009012 — intervention group
Group type: COMPARATOR
Intervention: Low-energy/fat diet (1200–1500 Kcal/day and 15–20% lipids)
Number of subjects: 80
Study 32452817 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Integrator smartphone app with additional telephone coaching
Number of subjects: 112
Study 32452817 — intervention group
Group type: COMPARATOR
Intervention: Health Integrator smartphone app without additional telephone coaching
Number of subjects: 112
Study 32032337 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic surveillance system without a dedicated rounder
Number of subjects: 1032
Study 32032337 — intervention group
Group type: COMPARATOR
Intervention: Electronic surveillance system with a dedicated rounder
Number of subjects: 1032
Study 32589939 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed fixation (rigid fixation for anterior fracture and nonrigid fixation for posterior fracture)
Number of subjects: 315
Study 32589939 — intervention group
Group type: COMPARATOR
Intervention: Nonrigid fixation for both fractures
Number of subjects: 315
Study 32589939 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed fixation
Number of subjects: 315
Study 32589939 — intervention group
Group type: COMPARATOR
Intervention: Nonrigid fixation
Number of subjects: 315
Study 32589939 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed fixation and Nonrigid fixation
Number of subjects: 315
Study 35850974 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Number of subjects: 0
Study 35850974 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 0
Study 35850974 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 35850974 — intervention group
Group type: EXPERIMENTAL
Intervention: current smokers
Number of subjects: 0
Study 33337110 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Volume/low-intensity training (HV)
Number of subjects: 30
Study 33337110 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity/low-volume training (HI)
Number of subjects: 30
Study 33337110 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30
Study 36007918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine exposure (maternal urine cotinine >5 ng/mL)
Number of subjects: 150
Study 36007918 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy nicotine exposure (>100 ng/mL)
Number of subjects: 150
Study 36007918 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild nicotine exposure (5-100 ng/mL)
Number of subjects: 150
Study 36007918 — intervention group
Group type: COMPARATOR
Intervention: Control (nonexposed to nicotine)
Number of subjects: 150
Study 34349460 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 160
Study 34349460 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 160
Study 32035729 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPT) with a battery of 12 aeroallergens
Number of subjects: 0
Study 32035729 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of relationship between sensitisation and asthma, rhinitis, or eczema
Number of subjects: 0
Study 32035729 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of sociodemographic factors and helminthic infection
Number of subjects: 0
Study 35312440 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 60
Study 35312440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 60
Study 32174360 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-to-auditory sensory substitution devices (SSDs) using The vOICe; specific dosage and duration not mentioned.
Number of subjects: 0
Study 32174360 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dichotic listening test; specific dosage and duration not mentioned.
Number of subjects: 0
Study 35771346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (400 kcal and 15 g protein daily, multivitamin tablets thrice weekly for 3 months)
Number of subjects: 80
Study 35771346 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 kcal and 2 g protein daily, placebo tablet thrice weekly for 3 months)
Number of subjects: 80
Study 32634840 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-based group intervention
Number of subjects: 25
Study 36326418 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Number of subjects: 40
Study 36326418 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition
Number of subjects: 40
Study 32005582 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered artesunate vaginal inserts (1, 2, or 3 five-day treatment cycles at study weeks 0, 2, and 4)
Number of subjects: 28
Study 32005582 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered artesunate vaginal inserts
Number of subjects: 28
Study 35427411 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib-rituximab (IR)
Number of subjects: 529
Study 35427411 — intervention group
Group type: COMPARATOR
Intervention: fludarabine, cyclophosphamide, and rituximab (FCR)
Number of subjects: 529
Study 32648834 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32371553 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA)
Number of subjects: 2356
Study 32371553 — intervention group
Group type: COMPARATOR
Intervention: HPV self‐sampling
Number of subjects: 2356
Study 32371553 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 2356
Study 33436922 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic Vector Optokinetic Perimetry (SVOP)
Number of subjects: 55
Study 33436922 — intervention group
Group type: COMPARATOR
Intervention: Standard Automated Perimetry (SAP)
Number of subjects: 55
Study 32116321 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D imaging system
Number of subjects: 40
Study 32116321 — intervention group
Group type: COMPARATOR
Intervention: 2D imaging system
Number of subjects: 40